Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11590062 | 0.87 | LMNA (0.35) | LMNATP53TSHRHTTHBB | |
| SCHEMBL11434836 | 0.82 | MEN1 (0.38) | LMNAMEN1KMT2ATSHR | |
| SCHEMBL514600 | 0.73 | SMN1; SMN2 (0.40) | MAPT | |
| SCHEMBL11220799 | 0.71 | CA2 (0.55) | LMNAMEN1KMT2AMAPTTP53 | |
| SCHEMBL15522987 | 0.71 | SMN1; SMN2 (0.30) | — | |
| Methane SCHEMBL11142383 | 0.71 | SMN1; SMN2 (0.39) | MAPT | |
| Sulfuric Acid SCHEMBL5988946 | 0.71 | SMN1; SMN2 (0.39) | MAPT | |
| SCHEMBL995245 | 0.71 | MEN1 (0.39) | LMNAMEN1KMT2AMAPTTP53 | |
| SCHEMBL999624 | 0.71 | CA1 (0.60) | TSHR | |
| SCHEMBL11580213 | 0.69 | CA1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6225347-B1 | FOR LOWERING BLOOD PRESSURE, INHIBITING PLATELET AGGREGATION, FOR LUTEOLYTIC EFFECT, HEALING ULCER, INHIBITING GASTRIC ACID SECRETION, AS CYTOPROTECTIVE AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-05-01 | — | — | US | claimed |
| US-5891910-A | 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-04-06 | — | — | US | claimed |
| US-9796695-B2 | Process for preparing benzofuran-2-carboxamide derivatives | SYMED LABS LIMITED (IN) | 2017-10-24 | — | — | US | disclosed |
| US-20170267655-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | SYMED LABS LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| US-9682946-B2 | Process for preparing benzofuran-2-carboxamide derivatives | SYMED LABS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| EP-2269611-B1 | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection | GEMMUS PHARMA INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150374715-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | GEMMUS PHARMA INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-8980944-B2 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | GEMMUS PHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120190739-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | GEMMUS PHARMA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8183286-B2 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | GEMMUS PHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2269611-A2 | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-4235930-A | INDUCTION OF MENSTRUATION OR ABORTION | SCHERING, A.G. (DE) | 1980-11-25 | — | — | US | disclosed |
| US-4219479-A | STABILIZED PROSTACYCLINS, HYPOTENSIVE AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-08-26 | — | — | US | disclosed |
| US-4191694-A | HYPOTENSIVE, ANTISECRETORY, ANTIULCER, ANTIARRHYTHMIA AGENTS; ANTICOAGULANTS, DIURETICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4178381-A | C-homoestratrienes | SCHERING, AKTIENGESELLSCHAFT (DE) | 1979-12-11 | — | — | US | disclosed |
| US-4159343-A | ABORTIFICANTS, LABOR INDUCTION, MENSTRUAL CYCLE REGULATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-06-26 | — | — | US | disclosed |
| US-4105792-A | OXYTOCICS, ABORTION INDUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
| US-4081537-A | PROGESTATIONAL, OVULATION INHIBITORS, NIDATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-03-28 | — | — | US | disclosed |
| US-4038410-A | ANTI-PROTOZOAN AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
| US-3951959-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267655-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | HTR3C, VIL1, HTR4 | LMNA 1710/4885MEN1 4630/4885KMT2A 718/4885 |
| US-20120190739-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | PTGER4, PTGER2, PTGER1 | LMNA 2281/4885MEN1 4323/4885KMT2A 777/4885 |
| US-20150374715-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | PTGER4, PTGER2, PTGER1 | LMNA 2281/4885MEN1 4323/4885KMT2A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.